# Prior Axitinib as a Determinant of Outcome of Renal Surgery

> **NCT03438708** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Diego** · enrollment: 22 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Axitinib Oral Tablet [Inlyta]

## Key facts

- **NCT ID:** NCT03438708
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-05
- **Primary completion:** 2026-03-04
- **Final completion:** 2026-03-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03438708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03438708, "Prior Axitinib as a Determinant of Outcome of Renal Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03438708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*